Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects. Cytarabine induces S phase arrest-mediated DNA da...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingyi, Wang, Yuetong, Yin, Chujie, Gong, Ping, Zhang, Zhenwei, Zhao, Linxiang, Waxman, Samuel, Jing, Yongkui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021233/
https://www.ncbi.nlm.nih.gov/pubmed/35443722
http://dx.doi.org/10.1038/s41419-022-04810-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021233/
https://www.ncbi.nlm.nih.gov/pubmed/35443722
http://dx.doi.org/10.1038/s41419-022-04810-z

Ejemplares similares